Shares of Galectin Therapeutics (NASDAQ:GALT) crater 46% premarket on robust volume in response to the company's webcast this morning. It was presenting data for its galactin inhibitor, GR-MD-02, as a treatment for fatty liver disease (NASH). Apparently, Slide 20 shows data that it has no effect on Galectin 3.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs